Enclomiphene vs Kisspeptin
Well Studied vs Emerging
synergistic Researched · 95% Kisspeptin stimulates GnRH neurons upstream of the pituitary while enclomiphene blocks estrogen negative feedback. Mechanistically complementary for HPTA activation.
Molecular Data
Enclomiphene Kisspeptin
Weight 405.96 Da 1,213.42 Da (KP-10) / 6,087 Da (KP-54)
Half-life ~10 hours ~4 minutes (KP-10), ~28-32 minutes (KP-54)
Chain — 10-54 amino acids
Type Trans-isomer of clomifene (selective estrogen receptor modulator) Neuropeptide family (RFamide)
Key Benefits
Enclomiphene
01 Raises endogenous testosterone by stimulating the HPTA axis
02 Preserves fertility and spermatogenesis (unlike exogenous testosterone)
03 No estrogenic agonist activity (unlike racemic clomifene/Clomid)
04 Oral dosing with no injections required
05 Does not suppress the HPTA or cause testicular atrophy
06 Effective for post-cycle therapy and secondary hypogonadism
07 Well-tolerated with a favorable side effect profile
Kisspeptin
01 Potent reproductive hormone stimulation (LH/FSH)
02 Restoration of natural testosterone production
03 Fertility enhancement
04 Sexual function support
05 Hypogonadism treatment potential
Dosing Protocols
Enclomiphene
12.5-25mg oral daily / Once daily (morning preferred)
Kisspeptin
100-200 mcg per injection / Single dose for testing, or 2-3 times weekly (NEVER daily - causes desensitization)
Gonadotropin stimulation 100-200mcg Single dose or 2-3x weekly
Fertility support 0.4-1.0 nmol/kg (50-150mcg) As directed by physician
Sexual function (clinical) 1 nmol/kg/h 75-minute IV infusion
Side Effects
Enclomiphene
Headache
Nausea or mild gastrointestinal discomfort
Hot flashes or flushing
Mood changes (irritability or emotional sensitivity)
Fatigue during initial adjustment
Kisspeptin
Minimal acute side effects reported
Potential mild cardiovascular effects
Contraindications
Known hypersensitivity to clomifene or enclomiphene
Pre-existing liver disease or significantly elevated liver enzymes
Active or history of thromboembolic disorders
Pregnancy or women who may become pregnant (teratogenic risk)
Primary hypogonadism (testicular failure -- enclomiphene requires functional testes)
Pituitary tumors or undiagnosed pituitary pathology
Not recommended during pregnancy or breastfeeding
Caution with cardiovascular disease history
Daily dosing causes receptor desensitization
Research Evidence
Enclomiphene Kisspeptin
Status Well Studied Emerging
References 5 studies 4 studies
Latest — 2025
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.